Introduction
Exposure to the organophosphorus insecticides (OP) is suspected to exert a negative impact on the developing nervous system in children. Despite the voluntary restrictions that have eliminated the use of many of these compounds from residential use in the United States, they are still used heavily in agriculture. Thus, the potential for childhood exposure to OP insecticides in agricultural communities still exists (Koch et al., 2002; Arcury et al., 2007) . Developmental exposure to OP insecticides has been suggested to have lasting negative impacts, including decreased motor skills, decreased cognitive abilities, increased signs of attention deficit disorder and attention deficit/hyperactivity disorder (ADHD), and altered brain morphology (Ruckart et al., 2004; Marks et al., 2010; Engel et al., 2011; Bouchard et al., 2011; Rauh et al., 2006 Rauh et al., , 2011 Rauh et al., , 2012 . Of the OP insecticides frequently linked to these issues, chlorpyrifos (CPF) is one of the most frequently applied (Grube et al., 2011) .
The canonical toxicological target for CPF is brain acetylcholinesterase (ChE), the inhibition of which results in the accumulation of acetylcholine and subsequent hyperactivity in the cholinergic system. However, multiple developmental studies have reported that CPF induces neurochemical and behavioral aberrations at dosage levels that do not produce characteristic signs of cholinergic hyperactivity and induce only minimal amounts of ChE inhibition (Levin et al., 2002; Slotkin et al., 2006 Slotkin et al., , 2007 Timofeeva et al., 2008a,b) . Such observations have led to the hypothesis that some of the developmental toxic effects of CPF occurs through non-cholinergic mechanisms.
Previous studies have reported the disruption of endocannabinoid metabolism following acute in vivo exposure of adult mice and rats to high dosages of OP compounds including CPF (Quistad et al., 2001 (Quistad et al., , 2002 (Quistad et al., , 2006 Nallapaneni et al., 2008; Nomura et al., 2008; Nomura and Casida, 2011; Liu et al., 2013 Liu et al., , 2015 . Work performed in our laboratory has expanded this work by investigating the effect of repeated low level CPF exposure on endocannabinoid metabolism in developing rats. Developmental CPF exposure resulted in significant inhibition of the brain endocannabinoid metabolizing enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) and significant elevation of their respective substrates the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) (Carr et al., 2011 (Carr et al., , 2013 . However, the levels of CPF used in these studies also resulted in significant inhibition of ChE activity even at the lowest dosage used (1.0 mg/kg). A subsequent study utilized a lower dosage (0.5 mg/kg) of CPF that yielded no measurable inhibition of ChE or MAGL, but induced significant inhibition of FAAH (Carr et al., 2014) . This dosage resulted in a significant elevation of brain AEA levels but no change in 2-AG levels.
Although these data demonstrate that developmental CPF exposure results in a biochemical disruption of the endocannabinoid system, it is not clear if this altered signaling results in any functional effects in the whole animal. Appropriate functioning of the endocannabinoid system is necessary for the control of the responses that are induced by environmental stimuli (Wotjak, 2005; Lutz, 2009) . Furthermore, the modulation of endocannabinoid signaling can alter normal responses (Naidu et al., 2007; Zanettini et al., 2011) . In addition, altering endocannabinoid signaling during development can induce persistent changes in anxiety (O'Shea et al., 2006) . It has also been demonstrated that developmental CPF induces changes in behaviors associated with anxiety (Aldridge et al., 2005; Ricceri et al., 2003 Ricceri et al., , 2006 Venerosi et al., 2006 Venerosi et al., , 2008 Venerosi et al., , 2010 Venerosi et al., , 2015 De Felice et al., 2014) , but these effects were observed at dosages that inhibit ChE.
One test of anxiety is the emergence test, which measures an animal's response to a novel environment (Archer, 1973) . This study was designed to determine the response of preadolescent rats exposed developmentally to CPF to a novel aversive environment by measuring the time required for a rat to emerge from a dark area (safe) into a well-lit area (novel aversive environment). In an attempt to obtain a dose response, two dosages previously demonstrated to induce biochemical effects (0.5 and 1.0 mg/kg) and a third new middle dosage (0.75 mg/kg) were utilized in the behavioral test. To match previous data, the activities of ChE, MAGL, and FAAH and the levels of the endocannabinoids AEA and 2-AG were determined in the forebrain at 12 h following the last administration of CPF. In addition, the levels of the non-cannabinoid N-acylethanolamides palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) in the brain were also determined. OEA and PEA are substrates for FAAH and genetic deletion or inhibition of FAAH activity also increases their levels (Cravatt et al., 1996; Fegley et al., 2005) . However, it is not clear whether the inhibition of FAAH resulting from low level exposure to CPF will result in changes in their levels.
Materials and methods

Chemicals
Chlorpyrifos (>99% purity) was a generous gift from DowElanco Chemical Company (Indianapolis, IN). All other chemicals were purchased from Cayman Chemicals (Ann Arbor, MI) or Sigma Chemical Co. (St. Louis, MO).
Animal treatment
Animals were housed in a temperature controlled (22 AE 2 8C) Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility with a 12-h dark-light cycle and with lights on between 0700 and 1900. LabDiet rodent chow and tap water were freely available during the experimentation. All procedures were approved by the Mississippi State University Institutional Animal Care and Use Committee. Adult male and female Sprague Dawley rats (CD IGS; Harlan Laboratories, Indianapolis, IN) were bred and following parturition, male and female rat pups within the same litter were assigned to different treatment groups. There were always representative control animals of the same sex present in each litter to match the CPF treated animals. For the behavioral portion of this project, rats from 15 litters were used. The day of birth was considered as postnatal day 0 (PND 0).
Chlorpyrifos was administered at a volume of 0.5 ml/kg body weight by oral gavage (per os) every day from PND10 through PND16, a time frame corresponding to the postnatal age in humans in which significant brain maturation occurs (Andersen, 2003; Counotte et al., 2011; Tau and Peterson, 2010) . Oral gavage was performed using a 25 ml tuberculin syringe equipped with a 1-in.
24-ga straight intubation needle (Popper and Sons, Inc., New Hyde Park, NY) to deliver the solution to the back of the throat. Daily body weights were recorded and weight gain was calculated as the difference between the body weights on PND11-16 and the original body weight at initiation of treatment on PND10.
The treatment groups selected for study were control (corn oil), low CPF (0.5 mg/kg), medium CPF (0.75 mg/kg), and high CPF (1 mg/kg). These dosages were designed to span the range between no inhibition of brain ChE and low inhibition of brain ChE (Carr et al., 2013 (Carr et al., , 2014 . These dosages are below the oral repeated No Observed Effect Level (NOEL) for signs of toxicity (4.5 mg/kg) for postnatal rats but do span the oral repeated NOEL for inhibition of brain ChE activity (0.75 mg/kg) as reported by Zheng et al. (2000) . However, it is unclear how these dosages compare to environmental exposure levels in children.
Behavioral testing
On PND25, each rat was subjected to an emergence test similar to that described by Smith et al. (1998) and Lalonde and Strazielle (2008 , 2009 with some modifications. The behavioral arena was a clear plexiglass open-field (28 Â 28 Â 46 cm). A black plexiglass barrier was present between the experimenter and the open-field to prevent the rat from observing the experimenter. The open-field contained a small stainless steel cup (7.5 Â 10.25 cm) that attached to the floor of one corner with the open end facing into the box. The room was illuminated by fluorescent lights resulting in a light intensity of 300 lx. Each test session was filmed and recorded using Limelight Video Tracking Software (Actimetrics, Wilmette, IL). The rats were naive to the testing room and the testing apparatus. On the day of testing, each rat was removed from its cage and carried to the testing room. Having been handled daily during treatment, the rats do not require physical restraint. The rat was then placed into the cup facing the enclosed end of the cup. The rat remained in the arena until it emerged (all four paws) into the open-field or until a 300 s time limit had elapsed. After each test, the open field and the cup were cleaned with 70% ethanol and water and dried with tissue.
Tissue collection
An additional cohort of non-behavioral rats were used to determine the activities of ChE, FAAH, and MAGL, the levels of the endocannabinoids AEA and 2-AG, and the levels of the non-cannabinoid N-acylethanolamides palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) in the forebrain of each treatment group. Rat pups were treated as described above with either corn oil or 0.5, 0.75 or 1.0 mg/kg CPF and then sacrificed at 12 h after the last administration of CPF on PND16, which is the time for peak inhibition of ChE and FAAH as determined by our previous time course study (Carr et al., 2013) . Brains were rapidly removed and dissected to obtain the forebrain (excluding the medulla and cerebellum). The forebrain was divided into right and left hemispheres and frozen on a stainless steel plate on top of dry ice, and maintained at À80 8C until assay. The forebrain was the region used to determine the level of enzyme inhibition and endocannabinoid levels in our previous studies (Carr et al., 2013 (Carr et al., , 2014 .
Enzyme assays
The activities of ChE, FAAH, and MAGL in the left forebrain were measured as previously described (Carr et al., 2011) . ChE activity was measured spectrophotometrically using a modification (Chambers et al., 1988) of Ellman et al. (1961) with acetylthiocholine as the substrate (1 mM final concentration) and 5,5 0 -dithiobis (nitrobenzoic acid) as the chromogen. FAAH and MAGL activities were measured using either 50 mM AEA or 2-AG as substrates, respectively, and arachidonic acid-d 8 as internal standard. The amount of arachidonic acid formed was determined by LC-MS as previously described (Xie et al., 2010) . Protein concentrations of tissue extracts were quantified with the Folin phenol reagent using bovine serum albumin as a standard (Lowry et al., 1951) . Specific activities were calculated as nmole (ChE) or pmole (FAAH or MAGL) product produced min
Endocannabinoid and N-acylethanolamide levels
The right forebrain was subjected to determination of the levels of 2-AG, AEA, OEA, and PEA as previously described (Carr et al., 2013) with some modifications as follows. Following homogenization in 1:1 v/v ethyl acetate: 0.1 M potassium phosphate (pH 7.0) containing known amounts of deuterated internal standards (2-AGd 8 , AEA-d 8 , OEA-d 4 , and PEA-d 4 ), the homogenate was centrifuged to obtain the organic layer. The organic fraction was dried under a stream of N 2 and the residue was resolubilized in 1:1 v/v water:methanol (100 ml). A 10 ml aliquot of the resolubilized lipid was injected onto an Acquity UPLC BEH C18 column (2.1 Â 100 mm, 1.7 mm), equipped with pre-column (2.1 Â 5 mm, 1.7 mm), interfaced with a Thermo Quantum Access triple-quadrupole mass spectrometer. The mobile phase was a blend of solvent A (0.1% acetic acid in water) and solvent B (0.1% acetic acid in methanol). The flow rate was 0.2 ml/min and analytes were eluted with the following gradient program: 0 min (15% A, 85% B), 0.5 min (15% A, 85% B), 3 min (5% A, 95% B), 6.9 min (5% A, 95% B), 7 min (15% A, 85% B), 9 min (15% A, 85% B). Single reaction monitoring ( The source settings were as follows: spray voltage, +3000 V; vaporizer temp, 400 8C; capillary temp, 325 8C; sheath gas pressure, 25 psi; aux gas pressure, 2 psi. Endocannabinoids are quantified by measuring the area under each chromatographic peak and comparing it to the area under the chromatographic peak for the appropriate deuterated internal standard, followed by correction for the ionization efficiency of AEA, 2AG, OEA and PEA relative to their deuterated standards (and the isotopic purity of the internal standard) which was empirically determined. The endocannabinoid amounts are normalized on the brain wet weight and expressed as pmol/g brain (AEA, OEA, and PEA) or nmol/g brain (2-AG).
Statistical analysis
Statistical analysis was performed using SAS statistical package (SAS Institute Inc., Cary, NC). The sphericity of the body weight gain data was initially tested by analysis of variance (ANOVA) using the general linear model with a repeated measures paradigm and was found to violate the assumption of sphericity. Therefore, subsequent analysis by ANOVA using the Mixed procedure (Littell et al., 1996) was conducted with a repeat measures paradigm with a Huynh-Feldt covariance structure (Huynh and Feldt, 1970) , followed by separation of means using least significant difference. The analysis identified significant differences in the main effects (sex, treatment, and day) and all possible interactions.
Enzyme specific activities and endocannabinoid/N-acylethanolamine concentrations were analyzed by ANOVA using the Mixed procedure to determine significant differences in sex, treatment, and any sex Â treatment interactions. All analyses included litter and sex Â treatment Â litter as random effects. Mean separation was performed by Least Significant Difference (LSD).
Behavioral data were subjected to Shapiro-Wilk's test to check the normality of the residuals and homoscedasticity of data and the data were not found to be sufficiently normally distributed. Accordingly, to determine statistical differences between the four treatment groups, a method similar to the non-parametric Friedman's test was conducted. Each sex was considered a block. For each outcome, the data was first ranked within each sex. An ANOVA using the GLM procedure was then conducted on the ranked data with treatment and sex as the explanatory variables. If treatment was found to have a significant effect, differences in least squares means with Tukey adjusted p-values were used to make pairwise comparisons among the treatment levels. The criterion for significance was set at p < 0.05 for all parameters.
Results
No signs of overt toxicity or cholinergic hyperstimulation, such as lacrimation, diarrhea, or tremors, were observed following CPF exposure. With respect to weight gain in females (Fig. 1A) and males (Fig. 1B) , there was no significant overall effect of sex but there was a significant overall effect of day (p < 0.0001) and a significant sex Â day interaction (p < 0.0125). However, there was no significant overall effect of treatment or the presence of any significant interactions involving treatment. The lack of effects on weight gain observed in the 0.5 mg/kg and 1.0 mg/kg treatment groups agree with our previous observations (Carr et al., 2011 (Carr et al., , 2014 .
With respect to enzyme inhibition following developmental exposure to CPF, there was no significant overall effect of sex and no significant sex Â treatment interaction with either ChE, MAGL, or FAAH. Therefore, male and female data were pooled for analysis for each enzyme. There was a significant effect of treatment for ChE (p < 0.0001), MAGL (p < 0.0062), and FAAH (p < 0.0001). With respect to ChE, significant inhibition of activity (19%) was observed in the high dosage group but no significant inhibition was present in the low or medium dosage groups ( Fig. 2A) . With respect to MAGL, significant inhibition of activity (12%) was observed in the high dosage group but no significant inhibition was present in the low or medium dosage groups (Fig. 2B) . With respect to FAAH, significant inhibition of activity was observed in the low (24%), medium (33%), and high (61%) dosage groups (Fig. 2C) . For the low and high dosages, these data are similar to levels of inhibition obtained previously (Carr et al., 2013 (Carr et al., , 2014 .
With respect to endocannabinoid levels following developmental exposure to CPF, there was no significant overall effect of sex and no significant sex Â treatment interaction with either AEA or 2-AG. Therefore, male and female data for each parameter were pooled for analysis. There was a significant effect of treatment for AEA (p < 0.0001) and 2-AG (p < 0.0008). With respect to AEA, there was a significant increase in the levels in the low (30%), medium (51%), and high (68%) dosage groups (Fig. 3A) . With respect to 2-AG, no effects were observed in the low dosage group but there was a significant increase in the levels in the medium (17%) and high (37%) dosage groups (Fig. 3B ). For the low and high dosages, these levels of increased AEA and 2-AG are similar to levels obtained previously (Carr et al., 2013 (Carr et al., , 2014 .
With respect to the N-acylethanolamine levels following developmental exposure to CPF, there was no significant sex -Â treatment interaction but there was a significant effect of sex for both OEA (p < 0.0002) and PEA (p < 0.0017). Therefore, male and female data for each parameter were analyze separately. For OEA, there was a significant effect of treatment in females (p < 0.0001) and males (p < 0.0001) with OEA levels significantly increased in all treatment groups in both sexes. However, the level of increase appeared to be greater in females than in males with increases of 72% and 43%, respectively, in the low dosage group; 94% and 63%, respectively, in the medium dosage group; and 104% and 96%, respectively, in the high dosage group (Fig. 4A and B) . For PEA, there was a significant effect of treatment in females (p < 0.0001) and males (p < 0.0001) with PEA levels significantly increased in Fig. 1 . Rates of weight gain of (A) female and (B) male rat pups exposed daily from postnatal day 10 through 16 to either corn oil (control), 0.5, 0.75, or 1.0 mg/kg chlorpyrifos (CPF). Values are expressed as weight AE SE (n = 13-23). all treatment groups in both sexes. As with OEA, the level of increase of PEA appeared to be greater in females than in males with increases of 93% and 55%, respectively, in the low dosage group; 126% and 110%, respectively, in the medium dosage group; and 135% and 118%, respectively, in the high dosage group (Fig. 5A and B). With respect to emergence behavior, there was an overall effect of sex (p < 0.0027) and treatment (p < 0.0044) but no significant sex Â treatment interaction. This indicates that developmental exposure to CPF altered normal emergence behavior in a similar manner regardless of sex. However, even though not statistically significant, treated females appeared to remain in the cup for a slightly longer period of time prior to emergence than did treated males ( Fig. 6A and B) . There was no observed dose-response effect on behavior; all dosage groups were statistically similar to one another, but all three dosages, low (p < 0.0014), medium (p < 0.0039), and high (p < 0.0076), were significantly different from control.
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Discussion
In the emergence test, the fact that the control rats preferred to remain in the safe area when placed in the novel environment indicated that the novel environment was an aversive one. It is very likely that the increased amount of light in this environment played a role. Rats are nocturnal and prefer dark areas but they do like to explore novel areas. The time it takes a rat to emerge from a dark area into a novel well-illuminated area is a measure of how it perceives its surrounding environment and how it reacts to that environment. The longer it takes for a rat to emerge is suggestive of a higher level of anxiety induced by the novel environment. The emergence test used in our study is the initial component that is measured in the light/dark test and this component has been reported to be a measure of anxiety-related behavior (Arrant et al., 2013) . Previous studies employing the emergence test have demonstrated that the classical anxiolytic drug diazepam decreases the latency to emerge in Sprague Dawley rats (Pare et al., 2010) and the classical anxiolytic drug chlordiazepoxide decreases the latency to emerge in BALB/c mice (Lalonde and Strazielle, 2010) . Our results suggest that the CPF-treated rats had reduced levels of anxiety compared to control rats.
Previous studies have demonstrated that developmental CPF exposure can disrupt behavior in tasks associated with anxiety. Anxiolytic responses were observed in the elevated plus maze behavioral test following postnatal exposure to CPF (Aldridge et al., 2005; Ricceri et al., 2006) ; however, gestational exposure resulted in either anxiogenic responses (Braquenier et al., 2010) or had no effect (Icenogle et al., 2004) . Furthermore, both gestational and postnatal exposures resulted in altered parameters associated with [ ( F i g . _ 6 ) T D $ F I G ] social interactions suggesting changes in social anxiety (Ricceri et al., 2003; Venerosi et al., 2006 Venerosi et al., , 2008 Venerosi et al., , 2010 Venerosi et al., , 2015 De Felice et al., 2014) . Thus, our data are consistent with previous work demonstrating that developmental CPF exposure can disrupt behaviors that can be influenced by anxiety levels. Importantly, however, the lowest dosages which produced effects in the previous studies were either 1.0 mg/kg or greater which causes significant ChE inhibition as demonstrated in Fig. 2A . Our study included dosages of CPF that did not inhibit ChE. Based on our biochemical data, the elevation of AEA, PEA, and/or OEA induced by the developmental exposure to CPF could play a role in the changes in behavior observed in the emergence test 9 days later.
The lack of ChE inhibition observed in the medium dosage group agrees with Zheng et al. (2000) who reported that the brain No Observed Effect Level (NOEL) for significant change in ChE activity following repeated developmental exposure was 0.75 mg/ kg. No significant inhibition was present with the lower dosage (0.5 mg/kg) and 19% inhibition was present with 1.0 mg/kg. Thus, our data indicate that the decreased anxiety-like behavior observed in preadolescent rats exposed developmentally to CPF occurs at dosages that either induce low levels of brain ChE inhibition or do not induce any inhibition. This suggests that the behavioral outcome is the result of the CPF exposure impacting a non-cholinergic target. In this study, all of our biochemical data was determined on PND16 after 7 days of treatment. It is possible that significant ChE inhibition could have been present during the earlier ages following exposure to the low dosages used in this study. However, Zheng et al. (2000) reported that the NOEL for significant alteration in brain ChE activity following acute oral exposure to CPF was 1.5 mg/kg on PND7. This suggests that none of our dosages at or below 1 mg/kg would likely have induced brain ChE inhibition following initial exposure on PND10. What is not clear is whether ChE inhibition is present after repeated exposures at the earlier ages such as PND11 or PND12. Future studies will be conducted to investigate this possibility.
At all three dosages of CPF, there was significant inhibition of FAAH activity but little effect on MAGL activity. Based on this and our previous studies, the inhibition of FAAH activity between 0.5 and 1.0 mg/kg is dose-related. There was also a dose-related increase in the levels of AEA and 2-AG. The significant increase in 2-AG in the medium dosage group was not accompanied by inhibition of MAGL. Our previous work demonstrated that in preweanling rat brain, only $45% of 2-AG hydrolysis is due to the action of MAGL (Carr et al., 2011) . This is in contrast to that observed in adult mice which is $85% (Blankman et al., 2007) . Other enzymes, including FAAH, have previously been reported to degrade 2-AG in vitro (Blankman et al., 2007) and it is possible that the inhibition of these enzymes could have disrupted normal 2-AG metabolism. While there were dose-related changes in the biochemical parameters measured in this study, there was not a dose-related response in emergence behavior. This suggests that all three dosages utilized in the present study are above the NOEL for the alteration of emergence behavior in preadolescent rats following developmental CPF exposure.
It is well documented that increasing AEA levels in adult brain, either by genetic deletion or pharmacological inhibition of FAAH activity, leads to anxiolytic behavior in multiple tests of anxiety (Kathuria et al., 2003; Patel and Hillard, 2006; Naidu et al., 2007; Moreira et al., 2008; Kinsey et al., 2011) . As stated earlier, OEA and PEA are also substrates for FAAH and genetic deletion or inhibition of FAAH activity increases their levels (Cravatt et al., 1996; Fegley et al., 2005) . OEA and PEA both exhibit antidepressant effects when administered prior to conducting animal tests of anxiety/depression (Crupi et al., 2013; Yu et al., 2011 Yu et al., , 2015 . In these studies, the dosages of FAAH inhibitor given to adult rodents were designed to produce a high level of FAAH inhibition in the brain and the testing occurred shortly after administration; however, little work has been done to investigate the persistent effects of developmental exposure to an inhibitor of FAAH activity. Exposure to the FAAH inhibitor URB597 during adolescence altered the levels of the CB1 receptor in adult rat brain (Marco et al., 2009 ) and led to increased anhedonia in adults (Macri et al., 2012) . Gestational exposure to URB597 led to subtle behavioral deficits in the offspring after they reached adult ages (Wu et al., 2014) . However, the dosages used in those developmental studies were also designed to produce substantial FAAH inhibition. In contrast, the highest dosage of CPF utilized in the present study only moderately inhibited FAAH activity (61%) with even lower inhibition at the lower two dosages. Based on our previous studies using the highest dosage of CPF (1.0 mg/kg), restoration of AEA levels to control levels occurred within 2 days following the last administration (Carr et al., 2013) . Thus, at the time of behavioral testing in the current study (9 days following the last administration), the CPF-induced reduction in the activity of FAAH and elevated AEA levels are likely not a direct factor in the observed behavioral outcome. Currently, it is unclear if OEA or PEA levels follow a similar pattern of recovery and future studies will determine this. However, based on the work of Fegley et al. (2005) , the patterns of recovery of AEA, OEA, and PEA levels following a single administration of URB597 in adult rats were very similar to each other suggesting that the pattern of recovery of OEA and PEA to control levels may not be that different from that of AEA in our repeated CPF exposure model.
One possible mechanism to the observed behavioral outcome is that the elevated AEA levels that occur during the exposure period induce changes in the endocannabinoid system that result in persistent negative effects on normal neurological processes controling the response to an aversive novel environment. Previous work demonstrated the long term effects caused by developmental exposure to the FAAH inhibitor URB597 (Marco et al., 2009; Macri et al., 2012; Wu et al., 2014) , making this a plausible hypothesis. However, this mechanism does not take the elevated OEA and PEA levels into consideration. OEA and PEA do not activate the CB1 receptor, rather they are agonists to the peroxisome proliferator activated receptor alpha (PPAR-a; Fu et al., 2003; Lo Verme et al., 2005) . There is, however, a connection between the endocannabinoid system and PPAR-a with respect to cognitive function. Previous studies have reported memory enhancement in adult male rats following administration of a FAAH inhibitor and abrogation of the enhancement by pretreatment with a PPAR-a antagonist (Mazzola et al., 2009 ). In addition, the memory enhancement was also blocked by pretreatment with a CB1 antagonist suggesting a synergism between PPAR-a and CB1. At this time, the role of PPAR-a in anxiety-like behavior, if any, is not clear. However, when considering the mechanistic basis for the persistent effects of developmental CPF exposure on anxiety-like behavior, the potential role of elevated levels of OEA and PEA, in addition to the elevated levels of AEA, should be considered as possibly exerting negative effects on the developing brain.
In conclusion, our previous findings indicated that developmental exposure to low levels of CPF during the preweanling exposure period alters endocannabinoid metabolism resulting in the accumulation of the endocannabinoids in the brain. Here, we demonstrate that this exposure paradigm also leads to accumulation of two non-cannabinoid N-acylethanolamides. Moreover, when tested 9 days after cessation of CPF treatment, this exposure disrupted anxiety-like behavior in preadolescent rats. Future studies will employ multiple behavioral tests to provide a more complete and reliable picture of the effect that low level developmental CPF exposure has on the anxiety state of an animal. To date, our data demonstrate that exposure to CPF, at dosages that do not yield significant inhibition of ChE, can induce biochemical changes in the endocannabinoid system and cause persistent disruption of behavior. The fact that behavioral effects have been demonstrated at dosages lower than those previouslyreported could contribute to the risk assessment of CPF. Nevertheless, additional studies are required to determine whether there is a mechanistic link between the neurochemical effects and the behavioral effects prior to considering the endocannabinoid system as a mechanistic target for use as an endpoint for risk assessment.
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